The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Physiogenex to present at the American Diabetes Association Scientific Sessions in Orlando, FL, USA, June 22nd -26th 2018

News detail

Return to all news & events

06/23/2018 Physiogenex to present at the American Diabetes Association Scientific Sessions in Orlando, FL, USA, June 22nd -26th 2018

Physiogenex will be presenting a hyperinsulinemic euglycemic clamp study differentiating insulin analogues in STZ-rats, a model of experimental diabetes.
The study will be presented by Dr. François Briand, Director of Research and Business Development, during the ADA 2018 poster session, on Monday June the 25th, from noon to 1pm, poster #1773-P.

If you wish to make an appointment during the meeting with Dr. François Briand to discuss about your drug development project, please contact us.